RNTX Fundamental Analysis - REIN THERAPEUTICS INC

Fundamental Rating

Overall RNTX gets a fundamental rating of 2 out of 10. We evaluated RNTX against 557 industry peers in the Biotechnology industry. While RNTX seems to be doing ok healthwise, there are quite some concerns on its profitability. RNTX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year RNTX has reported negative net income.

In the past year RNTX has reported a negative cash flow from operations.

In the past 5 years RNTX always reported negative net income.

RNTX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a decent Return On Assets value of -28.06%, RNTX is doing good in the industry, outperforming 69.12% of the companies in the same industry.

Looking at the Return On Equity, with a value of -30.71%, RNTX is in the better half of the industry, outperforming 76.84% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-28.06%
ROE	-30.71%
ROIC	N/A

ROA(3y)-64.32%

ROA(5y)-86.69%

ROE(3y)-74.12%

ROE(5y)-115.87%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

RNTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

There is no outstanding debt for RNTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -2.18, we must say that RNTX is in the distress zone and has some risk of bankruptcy.

RNTX has a Altman-Z score of -2.18. This is comparable to the rest of the industry: RNTX outperforms 52.24% of its industry peers.

There is no outstanding debt for RNTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-2.18

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

RNTX has a Current Ratio of 3.30. This indicates that RNTX is financially healthy and has no problem in meeting its short term obligations.

RNTX's Current ratio of 3.30 is on the low side compared to the rest of the industry. RNTX is outperformed by 62.66% of its industry peers.

A Quick Ratio of 3.30 indicates that RNTX has no problem at all paying its short term obligations.

The Quick ratio of RNTX (3.30) is worse than 60.68% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.3
Quick Ratio	3.3

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

EPS 1Y (TTM)N/A

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%70.93%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RNTX will show a very strong growth in Earnings Per Share. The EPS will grow by 22.85% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y78.68%

EPS Next 2Y36.17%

EPS Next 3Y22.85%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

RNTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year RNTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as RNTX's earnings are expected to grow with 22.85% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y36.17%

EPS Next 3Y22.85%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

RNTX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

REIN THERAPEUTICS INC

NASDAQ:RNTX (6/13/2025, 8:00:02 PM)

1.88

-0.09 (-4.57%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-15 2025-05-15/amc

Earnings (Next)08-12 2025-08-12

Inst Owners24.45%

Inst Owner ChangeN/A

Ins Owners0.09%

Ins Owner ChangeN/A

Market Cap41.64M

Analysts85

Price Target10.2 (442.55%)

Short Float %0.51%

Short Ratio2.96

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)15.2%

Min EPS beat(2)-5.04%

Max EPS beat(2)35.44%

EPS beat(4)1

Avg EPS beat(4)-320.99%

Min EPS beat(4)-820.61%

Max EPS beat(4)35.44%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-23.08%

EPS NQ rev (1m)0%

EPS NQ rev (3m)71.04%

EPS NY rev (1m)0%

EPS NY rev (3m)23.44%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.44
P/tB	4.29
EV/EBITDA	N/A

EPS(TTM)-3.17

EYN/A

EPS(NY)-0.55

Fwd EYN/A

FCF(TTM)-1.26

FCFYN/A

OCF(TTM)-1.26

OCFYN/A

SpS0

BVpS4.3

TBVpS0.44

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-28.06%
ROE	-30.71%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-64.32%

ROA(5y)-86.69%

ROE(3y)-74.12%

ROE(5y)-115.87%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.3
Quick Ratio	3.3
Altman-Z	-2.18

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)N/A

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%70.93%

EPS Next Y78.68%

EPS Next 2Y36.17%

EPS Next 3Y22.85%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-132.47%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-4.33%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-4.33%

OCF growth 3YN/A

OCF growth 5YN/A

REIN THERAPEUTICS INC (RNTX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens